Clearside Biomedical to Seek Business Sale Through Chapter 11 Proceedings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Bankruptcy Filing: Clearside Biomedical has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware, seeking to restructure its operations.
Asset Sale Process: The company plans to pursue an auction and sale process for its assets under Section 363 of the U.S. Bankruptcy Code, allowing interested parties to submit binding offers.
Management's Statement: CEO George Lasezkay stated that the decision to file for bankruptcy was made after thorough assessment of strategic options, believing it to be the best path for the company and its stakeholders.
Operational Continuity: Clearside has filed motions to ensure that normal operations continue during the bankruptcy process.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
